3-benzyl-2-methoxyquinoline-6-carbonitrile | 924633-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-benzyl-2-methoxyquinoline-6-carbonitrile
• CAS: 924633-02-3
• 化学式: C₁₈H₁₄N₂O
• 分子量: 274.322
• InChiKey: XNIQSOMZLOZFML-UHFFFAOYSA-N

物化性质

• 沸点：
  438.1±40.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  45.9
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-benzyl-2-methoxyquinoline-6-carbonitrile 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 3.0h， 以81%的产率得到3-[Bromo(phenyl)methyl]-2-methoxyquinoline-6-carbonitrile
  参考文献：
  名称：

  WO2007/14885

  摘要：

  公开号：
• 作为产物：
  描述：

  3-苄基-6-溴-2-氯喹啉 在 四(三苯基膦)钯 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 3-benzyl-2-methoxyquinoline-6-carbonitrile
  参考文献：
  名称：

  [EN] IL4I1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'IL4I1 ET MÉTHODES D'UTILISATION

  摘要：

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1 -related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.

  公开号：

  WO2023278222A1

文献信息

• ANTIBACTERIAL QUINOLINE DERIVATIVES
  申请人：Janssen Pharmaceutica NV

  公开号：EP1912948B1

  公开（公告）日：2015-09-09
• Antibacterial Quinoline Derivatives
  申请人：Guillemont Jerome Emile Georges

  公开号：US20080182855A1

  公开（公告）日：2008-07-31

  The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof, the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of a bacterial disease including a mycobacterial disease, particularly those diseases caused by pathogenic mycobacteria such as Mycobacterium tuberculosis, M. bovis, M. avium and M. marinum . Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of bacterial diseases and a process for preparing the claimed compounds.
• US7915292B2
  申请人：——

  公开号：US7915292B2

  公开（公告）日：2011-03-29
• WO2007/14885
  申请人：——

  公开号：——

  公开（公告）日：——
• [EN] IL4I1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'IL4I1 ET MÉTHODES D'UTILISATION
  申请人：[en]MERCK SHARP & DOHME LLC

  公开号：WO2023278222A1

  公开（公告）日：2023-01-05

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof wherein A, E, U, X, Y, Z, R1, R2and n are as defined herein. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1 -related diseases. Also provided herein are pharmaceutical compositions comprising the compounds of the invention, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier and methods of treatment with the compounds of the invention.